Trial Profile

A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jan 2026 According to a Merz Therapeutics, completed the regulatory submission for XEOMIN (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2-17 years in the European Union (EU) and European Economic Area (EEA).
26 Jan 2026 Results published in the Media Release
08 Dec 2025 According to a Merz Therapeutics, data from this trial will be presented at the TOXINS 2026 8th International Conference, taking place January 14 to 17, 2026, in Madrid, Spain.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com